Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
Open Access
- 1 June 2008
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 57 (6), 1723-1729
- https://doi.org/10.2337/db07-1472
Abstract
OBJECTIVE—The inhibition of gut and renal sodium-glucose cotransporters (SGLTs) has been proposed as a novel therapeutic approach to the treatment of diabetes. We have identified dapagliflozin as a potent and selective inhibitor of the renal sodium-glucose cotransporter SGLT2 in vitro and characterized its in vitro and in vivo pharmacology. RESEARCH DESIGN AND METHODS—Cell-based assays measuring glucose analog uptake were used to assess dapagliflozin's ability to inhibit sodium-dependent and facilitative glucose transport activity. Acute and multi-dose studies in normal and diabetic rats were performed to assess the ability of dapagliflozin to improve fed and fasting plasma glucose levels. A hyperinsulinemic-euglycemic clamp study was performed to assess the ability of dapagliflozin to improve glucose utilization after multi-dose treatment. RESULTS—Dapagliflozin potently and selectively inhibited human SGLT2 versus human SGLT1, the major cotransporter of glucose in the gut, and did not significantly inhibit facilitative glucose transport in human adipocytes. In vivo, dapagliflozin acutely induced renal glucose excretion in normal and diabetic rats, improved glucose tolerance in normal rats, and reduced hyperglycemia in Zucker diabetic fatty (ZDF) rats after single oral doses ranging from 0.1 to 1.0 mg/kg. Once-daily dapagliflozin treatment over 2 weeks significantly lowered fasting and fed glucose levels at doses ranging from 0.1 to 1.0 mg/kg and resulted in a significant increase in glucose utilization rate accompanied by a significant reduction in glucose production. CONCLUSIONS—These data suggest that dapagliflozin has the potential to be an efficacious treatment for type 2 diabetes.Keywords
This publication has 30 references indexed in Scilit:
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 DiabetesJournal of Medicinal Chemistry, 2008
- The promoter for the gene encoding the catalytic subunit of rat glucose-6-phosphatase contains two distinct glucose-responsive regionsAmerican Journal of Physiology-Endocrinology and Metabolism, 2007
- Active sugar transport in health and diseaseJournal of Internal Medicine, 2007
- Phlorizin: a reviewDiabetes/Metabolism Research and Reviews, 2004
- Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)Human Genetics, 2002
- Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic ratsEndocrinology, 1996
- Molecular Characteristics of Na+-coupled Glucose Transporters in Adult and Embryonic Rat KidneyOnline Journal of Public Health Informatics, 1995
- Overexpression of Glut4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice.JCI Insight, 1995
- The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.JCI Insight, 1994
- Phlorizin hydrolase: A β-glucosidase of hamster intestinal brush border membraneBiochimica et Biophysica Acta (BBA) - Biomembranes, 1969